Biotechnology company developing engineered cells and gene therapies for oncology, diabetes, autoimmune, and genetic diseases.
Profile & Fundamentals
Sana Biotechnology: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Sana Biotechnology Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Company profile record
Sana Biotechnology Inc
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Sana Biotechnology Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 188 East Blaine Street, Seattle, WA, United States, 98102
Leadership & scale
- Chief executive
- Dr. Steven D. Harr M.D.
- CEO year born
- 1970
- Full-time employees
- 142
- Fiscal year end
- December
- IPO date
- 2021-02-04
Fundamentals snapshot
- Market Cap
- USD 813.1M
- P/E
- --
- Revenue (Q2 26)
- USD 0.00
- Profit (Q2 26)
- USD -63.6M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 0.00
- Shares in public float
- 190.9M
- Insider ownership
- 6.08%
Reporting & identifiers
- Symbol
- SANA.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US7995661045
- Asset ID
- equity_c00d89f7-6119-50b5-b6ab-c857ce253878
Ownership
Shares Outstanding
Latest: 295.7M | Max: 295.7M | Min: 158.8M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
64.56%
190.9M latest reported shares
Insider Ownership
6.08%
Latest reported insider stake
Short Float
0.23%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2019-01-01 | 158,803,500 |
| 2020-01-01 | 175,315,000 |
| 2021-01-01 | 183,987,000 |
| 2022-01-01 | 190,420,000 |
| 2023-01-01 | 197,317,000 |
| 2024-01-01 | 236,299,000 |
| 2025-01-01 | 253,234,000 |
| 2026-01-01 | 295,667,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| FMR Inc | 37,430,284 | 12.5% | 2026-03-31 |
| Flagship Ventures Management, Inc. | 25,001,856 | 8.35% | 2026-06-30 |
| BlackRock Inc | 14,240,175 | 4.76% | 2026-03-31 |
| State Street Corp | 10,538,086 | 3.52% | 2026-03-31 |
| Fidelity Growth Company Fund | 10,495,617 | 3.78% | 2026-07-31 |
| Canada Pension Plan Investment Board | 10,218,400 | 3.41% | 2026-06-30 |
| State Street® SPDR® S&P® Biotech ETF | 7,468,981 | 2.69% | 2026-08-31 |
| Vanguard Capital Management, LLC | 7,434,724 | 2.48% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6,251,644 | 2.25% | 2026-08-31 |
| iShares Russell 2000 ETF | 4,735,749 | 1.71% | 2026-08-31 |
| Geode Capital Management, LLC | 4,181,973 | 1.4% | 2026-03-31 |
| Marex Group Ltd | 3,999,100 | 1.34% | 2026-03-31 |
| The Goldman Sachs Group Inc | 3,181,115 | 1.06% | 2026-03-31 |
| Fidelity Growth Company K6 | 3,119,059 | 1.12% | 2026-07-31 |
| Bank of America Corp | 2,946,861 | 0.98% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The company operates as a pure pre-commercial biotechnology developer, generating zero recurring product revenue while reporting a trailing twelve-month net loss of $212 million through mid-2026. Headline losses narrowed noticeably from historical peaks exceeding $340 million, but this improvement reflects strict survival measures rather than operational growth. Management aggressively restructured operations, halting early-stage oncology trials to protect remaining capital. Free cash flow burn has stabilized at approximately $135 million annually. While slowing cash consumption buys critical operational time, the absence of commercial revenue means the business remains completely dependent on external funding. Reported bottom-line improvements stem largely from non-cash accounting adjustments rather than commercial sales.
The company operates as a pure pre-commercial biotechnology developer, generating zero recurring product revenue while reporting a trailing twelve-month net loss of $212 million through mid-2026. Headline losses narrowed noticeably from historical peaks exceeding $340 million, but this improvement reflects strict survival measures rather than operational growth. Management aggressively restructured operations, halting early-stage oncology trials to protect remaining capital. Free cash flow burn has stabilized at approximately $135 million annually. While slowing cash consumption buys critical operational time, the absence of commercial revenue means the business remains completely dependent on external funding. Reported bottom-line improvements stem largely from non-cash accounting adjustments rather than commercial sales.
Revenue, Net Income, and Free Cash Flow
Latest: USD 0.00 | Max: USD 0.00 | Min: USD -344.2M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Traditional profit margin metrics are entirely undefined because the business produces no commercial revenue. Trailing twelve-month operating losses stand near $208 million, while return on equity remains deeply negative at minus 152%. These negative metrics reflect the heavy expense of conducting advanced cellular research without incoming customer receipts. Recent reductions in operating deficits reflect corporate austerity and workforce rationalization rather than genuine profit leverage. If its stem-cell therapies successfully achieve commercial regulatory approval, off-the-shelf allogeneic manufacturing could eventually produce software-like profit margins. Until human trials prove definitive efficacy, however, profitability remains purely theoretical.
Traditional profit margin metrics are entirely undefined because the business produces no commercial revenue. Trailing twelve-month operating losses stand near $208 million, while return on equity remains deeply negative at minus 152%. These negative metrics reflect the heavy expense of conducting advanced cellular research without incoming customer receipts. Recent reductions in operating deficits reflect corporate austerity and workforce rationalization rather than genuine profit leverage. If its stem-cell therapies successfully achieve commercial regulatory approval, off-the-shelf allogeneic manufacturing could eventually produce software-like profit margins. Until human trials prove definitive efficacy, however, profitability remains purely theoretical.
Profitability Margins
No history available.
Latest Profitability Ratios as of 2025-12-31
Gross Margin
--
Gross profit / revenue
Operating Margin
--
Operating income / revenue
Net Margin
--
Net income / revenue
FCF Margin
--
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2018-12-31 | Not reported | -13,247,000 | -13,955,000 |
| 2019-12-31 | 0 | -130,778,000 | -111,687,000 |
| 2020-12-31 | 0 | -278,637,000 | -161,854,000 |
| 2021-12-31 | 0 | -344,182,000 | -280,916,000 |
| 2022-12-31 | 0 | -266,388,000 | -310,926,000 |
| 2023-12-31 | 0 | -283,255,000 | -273,614,000 |
| 2024-12-31 | 0 | -266,759,000 | -256,583,000 |
| 2025-12-31 | 0 | -244,166,000 | -144,766,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2018-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2019-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2020-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2021-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2022-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2023-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2024-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2025-12-31 | Not reported | Not reported | Not reported | Not reported |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-10-01.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.